Evidence map›Paper›PMID 29477640›Full record

ArticleNeurobiology of disease2018

Differential effect of amyloid beta peptides on mitochondrial axonal trafficking depends on their state of aggregation and binding to the plasma membrane.

Liang Zhang, Sergey Trushin, Trace A Christensen, Utkarsh Tripathi, Courtney Hong, Rachel E Geroux, Kyle G Howell, Joseph F Poduslo, Eugenia Trushina

Open access · hybridAbstract read
In one paragraph

Article in Neurobiology of disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 53 citations in OpenAlex.

  1. Review
  2. Article
  3. Organelle abnormalities in Alzheimer's disease.Organelle (Tucson, Ariz.) · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Mitochondrial behavior when things go wrong in the axon.Frontiers in cellular neuroscience · 2022
    Review
  13. Article
  14. Disentangling Mitochondria in Alzheimer's Disease.International journal of molecular sciences · 2021
    Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Liang ZhangDepartment of Neurology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA. Electronic address: Zhang.liang@mayo.edu.
Sergey TrushinDepartment of Neurology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA. Electronic address: Trushin.Sergey@mayo.edu.
Trace A ChristensenMicroscopy and Cell Analysis Core Facility, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA. Electronic address: Christensen.Trace@mayo.edu.
Utkarsh TripathiDepartment of Neurology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA. Electronic address: Tripathi.Utkarsh@mayo.edu.
Courtney HongDepartment of Neurology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA.
Rachel E GerouxDepartment of Neurology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA. Electronic address: Geroux.Rachel@mayo.edu.
Kyle G HowellDepartment of Neurology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA; Microscopy and Cell Analysis Core Facility, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA. Electronic address: Howell.kyle@mayo.edu.
Joseph F PodusloDepartment of Neurology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA; Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA. Electronic address: poduslo@mayo.edu.
Eugenia TrushinaDepartment of Neurology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA. Electronic address: Trushina.eugenia@mayo.edu.
Mayo Clinic · US

Funding

Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
Mitochondrial Complex I as a Target for Neuroprotection in ADRF1AG055549 · NIA · MAYO CLINIC ROCHESTER · PI TRUSHINA, EUGENIA · 2017 to 2025
$7.0M
Mitochondrial dynamics and metabolomic biomarkers in neurodegenerative disordersR01ES020715 · NIEHS · MAYO CLINIC ROCHESTER · PI TRUSHINA, EUGENIA · 2011 to 2015
$1.8M
Small Molecule Mitochondria-Targeted Therapeutics for AD (Supplement)UH3NS113776 · NINDS · MAYO CLINIC ROCHESTER · PI TRUSHINA, EUGENIA · 2022 to 2022
$1.1M
NIA NIH HHS RF1 AG055549NIEHS NIH HHS R01 ES020715NINDS NIH HHS UH3 NS113776
6 · The paper itself

Abstract

Inhibition of mitochondrial axonal trafficking by amyloid beta (Aβ) peptides has been implicated in early pathophysiology of Alzheimer's Disease (AD). Yet, it remains unclear whether the loss of motility inevitably induces the loss of mitochondrial function, and whether restoration of axonal trafficking represents a valid therapeutic target. Moreover, while some investigations identify Aβ oligomers as the culprit of trafficking inhibition, others propose that fibrils play the detrimental role. We have examined the effect of a panel of Aβ peptides with different mutations found in familial AD on mitochondrial motility in primary cortical mouse neurons. Peptides with higher propensity to aggregate inhibit mitochondrial trafficking to a greater extent with fibrils inducing the strongest inhibition. Binding of Aβ peptides to the plasma membrane was sufficient to induce trafficking inhibition where peptides with reduced plasma membrane binding and internalization had lesser effect on mitochondrial motility. We also found that Aβ peptide with Icelandic mutation A673T affects axonal trafficking of mitochondria but has very low rates of plasma membrane binding and internalization in neurons, which could explain its relatively low toxicity. Inhibition of mitochondrial dynamics caused by Aβ peptides or fibrils did not instantly affect mitochondrial bioenergetic and function. Our results support a mechanism where inhibition of axonal trafficking is initiated at the plasma membrane by soluble low molecular weight Aβ species and is exacerbated by fibrils. Since trafficking inhibition does not coincide with the loss of mitochondrial function, restoration of axonal transport could be beneficial at early stages of AD progression. However, strategies designed to block Aβ aggregation or fibril formation alone without ensuring the efficient clearance of soluble Aβ may not be sufficient to alleviate the trafficking phenotype.

Indexed as

Amino Acid SequenceAmyloid beta-PeptidesAnimalsAxonsCell MembraneCells, CulturedFemaleHippocampusHumansMiceMice, Inbred C57BLMice, TransgenicMitochondriaPregnancyProtein AggregatesProtein BindingAmyloid beta-PeptidesProtein AggregatesAggregationAlzheimer's diseaseAmyloid beta peptidesAtomic force microscopyAxonal transportBioenergeticsDynamic light scatteringElectron microscopyEndocytosisFibrilsMitochondriaMitochondrial functionMouse models of ADOligomersPlasma membrane bindingPrimary neuronsSeahorse extracellular flux analyzer

Identifiers

PMID29477640
PMCPMC5926207
OpenAlexW2791985271

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.